DiaSorin SpA (OTCMKTS:DSRLF) – Jefferies Financial Group issued their FY2019 earnings per share (EPS) estimates for DiaSorin in a report issued on Wednesday, June 12th. Jefferies Financial Group analyst P. Welford forecasts that the company will post earnings of $3.72 per share for the year. Jefferies Financial Group also issued estimates for DiaSorin’s FY2020 earnings at $3.99 EPS, FY2021 earnings at $4.28 EPS and FY2022 earnings at $4.61 EPS.
DSRLF stock opened at $114.75 on Friday. DiaSorin has a twelve month low of $80.10 and a twelve month high of $114.75.
DiaSorin S.p.A. develops, produces, and commercializes diagnostic tests in various clinical areas for hospital and private testing laboratories in the market of immunodiagnostics and molecular diagnostics. It offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; stool diagnostics; autoimmunity; and cardiac and brain damages.
Featured Article: CBOE Russell 2000® Volatility Index
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.